Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)
4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)
4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)
4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)
4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)
4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)
DEF 14A - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
PRE 14A - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
8-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and EuropeFDA Expressed No Safety Concerns Over Study Design and Duration of DosingFirst-Ever Formal Clinical Study for a Potential Peeling Skin Syndrome TherapySecond Cleared IND Indication for QRX003, in Addition to Netherton SyndromePeeling Skin Syndrome Currently Has No Approved TreatmentQuoin Anticipates Also Testing QRX003 in Additional Ichthyosis Indications for Which There Are No Approved Treatments ASHBURN, Va., July 09, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and
ASHBURN, Va., June 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 18/428,570, titled "Combination Treatment for Netherton Syndrome." The patent supports Quoin’s intellectual property strategy for QRX003, its investigational treatment for Netherton Syndrome, a rare genetic skin disease for which there are currently no approved treatments. Key Facts The USPTO has issued a Notice of Allowance for U.S. Pate
QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDAPivotal Phase 3 Study Expected to Initiate in the Second Half of 2026, with Potential NDA Filing in 2027Positive Clinical Update from Ongoing Pediatric Compassionate Use Program Released on June 16QRX003 Remains on Track to Potentially Become the First Approved Treatment for Netherton Syndrome ASHBURN, Va., June 23, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food
ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its new Chief Financial Officer as the Company advances its lead product candidate, QRX003, through pivotal clinical studies and prepares for potential commercialization. Quoin has appointed Sally Lawlor, BCL, FCA, as its new Chief Financial Officer, effective immediately. Ms. Lawlor is an accomplished finance executive with over 20 years of experience in financial leadership roles in public and private companies as well as a Big Four accounting fir
SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)
SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)
SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)
– Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome – Submitted Application to Japanese MHLW for Orphan Drug Designation (ODD) for QRX003; MHLW Confirmed QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Review – U.S. FDA Granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome, Complementing Previously Granted Orphan Drug and Rare Pediatric Disease Designations – Constructive Type C Meeting with FDA: Single Phase 3 Study May Be Sufficient to Support U.S. Marketing Approval; FDA Open to Trial Design Without Traditional Vehicle or Placebo Control – Rare Pediatric Disease Prior
- Positive 6 Month Clinical Data Reported for Ongoing Pediatric Netherton Syndrome Study - FDA Clears Second Pivotal Study of QRX003 for Netherton Syndrome - Initial Positive Data Announced from Peeling Skin Syndrome Pediatric Study - Orphan Drug Designation Granted by European Medicines Agency for QRX003 - Rare Pediatric Disease Designation Awarded by U.S. FDA - NETHERTON NOW Campaign Expanded with New Patient and Expert Video Releases ASHBURN, Va., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases provided a corporate upda
Continued Progress in Ongoing Late-Stage Netherton Syndrome Studies Announced Positive Clinical Data for Adult and Pediatric Netherton Patients Provided Clear Visual Evidence of QRX003 Mechanism of Action Patent Portfolio Expanded to Support Pipeline GrowthLaunch of NETHERTON NOW Advocacy Initiative ASHBURN, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the quarter ended March 31, 2025. Quoin CEO Dr. Michael Myers